Cannabinoid Encyclopedia

How cannabinoids work

What is PPAR-alpha?

A simple explanation of PPAR-alpha, why cannabinoid researchers study it, and what its biology can and cannot tell us.

Updated July 2026 31 research sources Mostly early-stage research

The short answer

Where PPAR-alpha fits into cannabinoid biology

PPAR-alpha is a biological target studied to understand how cannabinoids affect cells and signaling. Research on THC, CBG, CBC, and CBDA helps explain possible mechanisms. This page brings together 5 human-study sources, 17 research reviews, and 9 lab, animal, or mechanism sources. Most of the current evidence is preclinical or focused on biological mechanisms. A mechanism alone does not prove that a cannabinoid will produce a health benefit in people. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about PPAR-alpha.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on PPAR-alpha covers THC, CBG, and CBC; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about PPAR-alpha

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

THC

Studies examine how THC connects with PPAR-alpha or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 2

Too limited for a firm answer

CBG

Studies examine how CBG connects with PPAR-alpha or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 3

Too limited for a firm answer

CBC

Studies examine how CBC connects with PPAR-alpha or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 3

Mostly mechanism-focused

CBDA

Studies examine how CBDA connects with PPAR-alpha or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 4

Too limited for a firm answer

Anandamide

Studies examine how Anandamide connects with PPAR-alpha or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 5

Too limited for a firm answer

Endocannabinoids

Studies examine how Endocannabinoids connects with PPAR-alpha or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 6

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

5 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

17 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

9 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on PPAR-alpha is not one kind of study. This source set includes 16 narrative or expert reviews, 9 animal studies, 4 cell or laboratory studies, and 1 clinical study in people. 3

The recorded populations or models include people or patients (8 sources), animal models (7 sources), and cells or tissue models (7 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is pEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms (11 sources), oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms (10 sources), and gPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology (4 sources). Closely related outcome names can still describe different measurements. 5

The PPAR-alpha source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.

On this page, this source examines Endocannabinoids activity involving GPR119 and OEA and oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms. 1

Study type
narrative or expert review
Outcome focus
gPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology and oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
evidence still limited

narrative or expert review

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.

On this page, this source examines THC and endocannabinoids and endocannabinoid-like lipids research topics. 2

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
endocannabinoids and endocannabinoid-like lipids research topics
Evidence stage
evidence still limited

cell or laboratory study

Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.

On this page, this source examines CBG and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns and CBC and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns. 3

Study type
cell or laboratory study
Population or model
cells or tissue models
Outcome focus
safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns
Evidence stage
evidence still limited

animal study

Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats.

On this page, this source examines CBDA and nausea-related or inflammation-related outcomes. 4

Study type
animal study
Population or model
animal models
Outcome focus
nausea-related or inflammation-related outcomes
Evidence stage
mechanism-focused research

narrative or expert review

Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.

On this page, this source examines Anandamide and anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. 5

Study type
narrative or expert review
Outcome focus
anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on PPAR-alpha should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 3

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What does PPAR-alpha do?

PPAR-alpha is studied as part of cannabinoid-related biology and signaling. The exact role depends on the tissue, compound, and experimental setting. 7

Does a biological mechanism prove a health effect?

No. A mechanism can explain why an idea is plausible, but human studies are needed to test whether it changes a health outcome. 8

What research is linked to PPAR-alpha?

The main areas on this page include THC, CBG, CBC, and CBDA. The source links show the study type behind each area. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. narrative or expert review; evidence still limited PubMed 30537148 DOI 10.1002/jcp.27913
  2. 2
    Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. narrative or expert review; evidence still limited PubMed 17704824 DOI 10.1038/sj.bjp.0707423
  3. 3
    Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. cell or laboratory study; evidence still limited PubMed 42352060 DOI 10.3390/antiox15060754
  4. 4
    Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats. animal study; mechanism-focused research PubMed 31897571 DOI 10.1007/s00213-019-05428-4
  5. 5
    Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. narrative or expert review; evidence still limited PubMed 36150527 DOI 10.1016/j.plipres.2022.101194
  6. 6
    Endocannabinoids and nutrition. narrative or expert review; evidence still limited PubMed 18426507 DOI 10.1111/j.1365-2826.2008.01687.x
  7. 7
    Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. animal study; mechanism-focused research PubMed 35176443 DOI 10.1016/j.bbi.2022.02.008
  8. 8
    Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. systematic review or meta-analysis; evidence still limited PubMed 33919499 DOI 10.3390/nu13041346
  9. 9
    Probiotics and palmitoylethanolamide (PEA) for osteoarthritic pain: individual effects in a multiple baseline design study. clinical study in people; mechanism-focused research PubMed 41709243 DOI 10.1186/s12906-025-05187-0
  10. 10
    A fatty gut feeling. narrative or expert review; evidence still limited PubMed 23567058 DOI 10.1016/j.tem.2013.03.001
  11. 11
    Brain molecules and appetite: the case of oleoylethanolamide. narrative or expert review; evidence still limited PubMed 23464987 DOI 10.2174/1871524911313010010
  12. 12
    Classical endocannabinoid-like compounds and their regulation by nutrients. narrative or expert review; evidence still limited PubMed 24677570 DOI 10.1002/biof.1158
See all 31 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats. animal study; mechanism-focused research / 1 linked research note PubMed 31897571
  2. Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 31325449
  3. Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. animal study; mechanism-focused research / 2 linked research notes PubMed 35176443
  4. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. narrative or expert review; evidence still limited / 1 linked research note PubMed 17704824
  5. Classical endocannabinoid-like compounds and their regulation by nutrients. narrative or expert review; evidence still limited / 2 linked research notes PubMed 24677570
  6. Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. cell or laboratory study; evidence still limited / 2 linked research notes PubMed 42352060
  7. Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 35628241
  8. Endocannabinoids and nutrition. narrative or expert review; evidence still limited / 2 linked research notes PubMed 18426507
  9. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. narrative or expert review; evidence still limited / 2 linked research notes PubMed 19285259
  10. Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies. narrative or expert review; evidence still limited / 1 linked research note PubMed 42144898
  11. Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. narrative or expert review; evidence still limited / 2 linked research notes PubMed 30537148
  12. Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. narrative or expert review; evidence still limited / 1 linked research note PubMed 36150527
  13. A fatty gut feeling. narrative or expert review; evidence still limited / 1 linked research note PubMed 23567058
  14. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. animal study; mechanism-focused research / 1 linked research note PubMed 17449181
  15. Regulation of food intake by oleoylethanolamide. narrative or expert review; evidence still limited / 1 linked research note PubMed 15770421
  16. Brain molecules and appetite: the case of oleoylethanolamide. narrative or expert review; evidence still limited / 1 linked research note PubMed 23464987
  17. The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice. animal study; mechanism-focused research / 1 linked research note PubMed 29936173
  18. Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy. animal study; mechanism-focused research / 1 linked research note PubMed 30702457
  19. Regulation of Cholesterol and Triglyceride Metabolism by Fatty acid Ethanolamides. narrative or expert review; evidence still limited / 1 linked research note PubMed 42068417
  20. Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain. narrative or expert review; evidence still limited / 1 linked research note PubMed 39714723
  21. The search for the palmitoylethanolamide receptor. narrative or expert review; evidence still limited / 1 linked research note PubMed 15963531
  22. Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40563990
  23. Probiotics and palmitoylethanolamide (PEA) for osteoarthritic pain: individual effects in a multiple baseline design study. clinical study in people; mechanism-focused research / 1 linked research note PubMed 41709243
  24. Protective effect of palmitoylethanolamide in a rat model of cystitis. animal study; mechanism-focused research / 1 linked research note PubMed 25463999
  25. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 33919499
  26. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). narrative or expert review; evidence still limited / 1 linked research note PubMed 24602801
  27. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. narrative or expert review; evidence still limited / 1 linked research note PubMed 22697514
  28. Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. animal study; mechanism-focused research / 1 linked research note PubMed 27720681
  29. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. animal study; mechanism-focused research / 1 linked research note PubMed 28336953
  30. Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat. narrative or expert review; evidence still limited / 1 linked research note PubMed 24681513
  31. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. animal study; preclinical research / 1 linked research note PubMed 18316044